How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Urogenital Model Market
- By Model Type: In vitro models, In vivo models, Ex vivo models, Computational models
- By Application: Drug discovery and development, Disease modeling, Toxicity testing, Regenerative medicine research, Personalized medicine
- By Model Organism: Rodent models, Porcine models, Non-human primate models, Human cell-based models
- By Disease Focus: Bladder cancer models, Prostate cancer models, Urinary tract infection models, Interstitial cystitis models, Benign prostatic hyperplasia models
- By End User: Pharmaceutical and biotechnology companies, Academic and research institutes, Contract research organizations (CROs), Hospitals and clinical research centers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - In vitro models leads By Model Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 298 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.180 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.188 →
Full report · locked preview
Everything inside the Urogenital Model Market report
A complete, evidence-based study - 12 chapters and 125 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Model Type 4
Application 5
Model Organism 4
Disease Focus 5
End User 4
Companies profiled
Organovo Holdings Inc.
InSphero AG
Mimetas BV
Emulate Inc.
TissUse GmbH
Hurel Corporation
CN Bio Innovations Ltd.
Cellink (now part of BICO Group)
Axol Bioscience Ltd.
ReproCELL Inc.
Allevi Inc. (now part of 3D Systems)
Cytograft Tissue Engineering Inc.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Organovo Holdings Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →InSphero AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Mimetas BV
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Emulate Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →TissUse GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Hurel Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →CN Bio Innovations Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Cellink (now part of BICO Group)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Axol Bioscience Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →ReproCELL Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Allevi Inc. (now part of 3D Systems)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Cytograft Tissue Engineering Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →MatTek Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →EpiBone Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Biorep Technologies
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,011M by 2033 · 5.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- In vitro models57.8
- In vivo models9.5
- Ex vivo models20.1
- Computational models12.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,095M → $1,759M · 6.1%
Europe$762.9M → $1,216M · 6.0%
Asia Pacific$696.6M → $1,077M · 5.6%
Latin America$431.2M → $722.3M · 6.7%
Middle East and Africa$331.7M → $553.2M · 6.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.242026
5.262027
5.282028
5.272029
5.292030
5.312031
5.322032
5.332033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Organovo Holdings Inc.12.6
- InSphero AG9.8
- Mimetas BV14.9
- Emulate Inc.14.0
- TissUse GmbH11.9
- Hurel Corporation8.7
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Model Type14.4%
Application29.6%
Model Organism21.1%
Disease Focus22.4%
End User12.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.0
- Europe22.8
- Asia Pacific20.2
- Latin America13.6
- Middle East and Africa10.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Organovo Holdings Inc. | 85 | 97 | 98 | 95 | 88 | 76 | 90 |
| InSphero AG | 78 | 85 | 92 | 70 | 73 | 89 | 81 |
| Mimetas BV | 85 | 76 | 87 | 86 | 72 | 84 | 82 |
| Emulate Inc. | 66 | 72 | 80 | 79 | 62 | 75 | 72 |
| TissUse GmbH | 64 | 77 | 55 | 54 | 54 | 53 | 60 |
| Hurel Corporation | 54 | 64 | 48 | 68 | 56 | 67 | 60 |
| CN Bio Innovations Ltd. | 49 | 53 | 52 | 48 | 53 | 58 | 52 |
| Cellink (now part of BICO Group) | 54 | 44 | 55 | 36 | 35 | 49 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Organovo Holdings Inc.
- InSphero AG
- Mimetas BV
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Organovo Holdings Inc. | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| InSphero AG | ◐ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Mimetas BV | ✓ | ◐ | ✓ | ✓ | ◐ | ◐ |
| Emulate Inc. | ✓ | ◐ | ◐ | ✓ | − | ◐ |
| TissUse GmbH | − | ✓ | − | ◐ | ◐ | ◐ |
| Hurel Corporation | ◐ | ◐ | ◐ | ✓ | − | − |
| CN Bio Innovations Ltd. | − | − | ◐ | − | − | − |
| Cellink (now part of BICO Group) | ◐ | − | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Organovo Holdings Inc.90
2Mimetas BV82
3InSphero AG81
4Emulate Inc.72
5TissUse GmbH60
6Hurel Corporation60
7CN Bio Innovations Ltd.52
8Cellink (now part of BICO Group)46
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Organovo Holdings Inc.InSphero AGMimetas BV
Challenger1
Strong scale, closing on the leaders.
Emulate Inc.
Contender2
Focused players with pockets of strength.
TissUse GmbHHurel Corporation
Niche2
Specialists in a single segment or region.
CN Bio Innovations Ltd.Cellink (now part of BICO Group)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Model Type in North America, then scale across Urogenital Model Market — a $448M beachhead inside a $7.82B market.
Beachhead (SOM)$448Mobtainable near-term
Serviceable (SAM)$2.96Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
In vitro models
Best fit — highest urgency & budget in Model Type.
Economic buyer80 fit
In vivo models
Strong fit — clear ROI and a fast path to value.
End user67 fit
Ex vivo models
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Model Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Model Organism
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel31%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Model Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Urogenital Model Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified26%
Evaluation12%
Closed-won7%
$8.9KCAC
$40KLTV
4.5:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Urogenital Model Market is a durable-growth opportunity — $1.49B by 2033, compounding at 7.9%.
TAM · 2025$812Mtoday
TAM · 2033$1.49Bforecast
CAGR7.9%2027–2033
Cumulative$10.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.49BTotal addressable market
SAM$576MServiceable available market
SOM$94MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.9% CAGR
Demand compounds through 2033, outpacing GDP across Model Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Model Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.49BLarge & growingTAM by 2033 at 7.9% CAGR
$576MServiceable nowreachable with today’s model
$94MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.16BBear5.1% CAGR
$1.49BBase7.9% CAGR
$1.91BBull10.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Urogenital Model Market — a $5.78B market by 2033. Plan: grow share from 9.9% to 17.4%.
Market size · 2033$5.78Btotal addressable
Market CAGR7.0%2027–2033
Target share17.4%from 9.9% today
Revenue ambition$1.01Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.9% | 17.4% | On track |
| Revenue | $569M | $1.01B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 36.7% | 39.2% | Behind |
| Customer retention | 90.3% | 96.7% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Model Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Model Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $108M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Model Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAhead
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Urogenital Model Market conversation — a $5.57B market you can size, segment and defend in minutes.
Market size · 2033$5.57Btotal opportunity
Growth5.3%CAGR to 2033
Addressable buyers1,220+accounts in scope
Typical ROI7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Model Type
Goal Grow share in Model Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7×return on cost, year one
< 3 mopayback period
$50K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Organovo Holdings Inc.InSphero AGMimetas BVEmulate Inc.TissUse GmbHHurel CorporationCN Bio Innovations Ltd.Cellink (now part of BICO Group)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Urogenital Model Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Urogenital Model Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Uroendoscopy Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportUrodynamics Machine Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportUrodynamic Manometer Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportUrodynamic Analyzer Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportUrine Test Strip Analyzer Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportUrine Testing Equipment Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportUrine Test Analysis Market
Market size, share, segmentation and regional forecast.
$866M market · 2025 base year
View reportUrine Specimen Container Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportUrine Sediment Testing Equipment Market
Market size, share, segmentation and regional forecast.
$631M market · 2025 base year
View reportUrine Sample Test Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportUrine Sample Container Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportUrine Reagent Kit Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.